CHRS - CIK 0001512762
The table below shows Coherus BioSciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$138.51M | -$20.44M | -$174.88M | -$241.12M | -$37.43M | $154.15M |
| Capital expenditure | - | - | $286.00K | $2.04M | $1.29M | $7.23M |
| Investing cash flow | $375.09M | $230.32M | $144.64M | -$166.85M | -$138.41M | -$14.40M |
| Dividends paid | - | - | - | - | - |
Coherus BioSciences, Inc. reported operating cash flow of -$138.51M for fiscal year 2025. That is down 577.7% from -$20.44M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$252.54M (FY 2016) to -$138.51M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$273.70M | -$186.97M | $69.60M | $54.33M | $51.88M | $223.95M |